Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AAM Criticizes Lower Health Care Costs Act

Over Inclusion Of ‘Blocking Act’ Reforms To 180-Day Exclusivity

Executive Summary

Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.

You may also be interested in...

AAM Welcomes Passage Of CREATES Act

Industry has welcomed the passage of the CREATES Act in the US, which is aimed at curbing originator attempts to deny access to samples by abusing FDA safety programs.

US Industry Fears Blocking Bill Would Weaken Exclusivity

US industry fears draft legislation would weaken the 180-day exclusivity incentive to challenge patents; but it is more positive about planned reforms to rebate frameworks.

Trump’s US price policy aims to remove barriers

Ending the “gaming of regulatory and patent processes by drug makers to unfairly protect monopolies”, advancing biosimilars and generics to encourage greater competition and offering free generics to low-income seniors are among the measures set out in a “blueprint to lower drug prices” that has just been announced by US President Donald Trump. Billing the reform as “the most sweeping action in history to lower the price of prescription drugs for the American people”, Trump said his administration would be “eliminating the middlemen” and targeting ‘freeloading’ other countries.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts